Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (6): 1111-1114.doi: 10.3969/j.issn.1673-8225.2011.06.036

Previous Articles     Next Articles

Application of induced pluripotent stem cells in regenerative medicine

Liu Yu-kai1, Luo Hu1, Li Ze-gui2   

  1. 1Trainees Brigade Team 17, Third Military Medical University of Chinese PLA, Chongqing  400038, China
    2Department of Pharmacognosy, College of Pharmacy, Third Military Medical University of Chinese PLA, Chongqing  400038, China
  • Received:2010-09-22 Revised:2010-11-01 Online:2011-02-05 Published:2011-02-05
  • Contact: Li Ze-gui, Doctor, Professor, Department of Pharmacognosy, College of Pharmacy, Third Military Medical University of Chinese PLA, Chongqing 400038, China lizegui@tmmu.edu.cn
  • About author: Liu Yu-kai, Trainees Brigade Team 17, Third Military Medical University of Chinese PLA, Chongqing 400038, China liuyukai12345678@163.com
  • Supported by:

     the Innovation Foundation of the Third Military Medical University of Chinese PLA, No. 2007XG42*

PDF

381

Abstract:

BACKGROUND: Traditional transplantation of organs and cells would induce immunologic rejection and have some problems such as ethics and shortage of donor. Induced pluripotent stem (iPS) cells have self-renewal ability and differentiational potential as embryonic stem cells, and have genetic materials identical to patients, which avoids immunologic rejection. Thus, its application is broad.
OBJECTIVE: To review the current research about the progress of iPS cells in regenerative medicine.
METHODS: The PubMed database (http://www.ncbi.nlm.nih.gov/PubMed) was retrieved by computer to search the correlative documents published between 1997 and 2010 with the key words of “induced pluripotent stem cell, diabetes, Parkinson’s disease, cardiovascular” in English. Totally 322 papers were primarily gotten. Finally, 30 papers were included.
RESULTS AND CONCLUSION: Patient-specific iPS cell is induced from the patients themselves, so that it has the same genetic material and reduces the possibility of immunologic rejection. It also avoids the ethics problem. Thus, iPS cells have very large potential and broad prospect.

CLC Number: